ID   VRK2_HUMAN              Reviewed;         508 AA.
AC   Q86Y07; B4DKL0; D6W5D4; D6W5D6; Q49AK9; Q53EU9; Q53S39; Q53S77; Q53TU1;
AC   Q86Y08; Q86Y09; Q86Y10; Q86Y11; Q86Y12; Q8IXI5; Q99987;
DT   10-OCT-2003, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 3.
DT   12-OCT-2022, entry version 200.
DE   RecName: Full=Serine/threonine-protein kinase VRK2;
DE            EC=2.7.11.1 {ECO:0000269|PubMed:16495336, ECO:0000269|PubMed:16704422};
DE   AltName: Full=Vaccinia-related kinase 2;
GN   Name=VRK2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY, AND VARIANT
RP   VAL-167.
RC   TISSUE=Liver;
RX   PubMed=9344656; DOI=10.1006/geno.1997.4938;
RA   Nezu J., Oku A., Jones M.H., Shimane M.;
RT   "Identification of two novel human putative serine/threonine kinases, VRK1
RT   and VRK2, with structural similarity to Vaccinia virus B1R kinase.";
RL   Genomics 45:327-331(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), IDENTIFICATION (ISOFORM 1),
RP   FUNCTION, CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, TISSUE SPECIFICITY,
RP   AUTOPHOSPHORYLATION, AND VARIANT VAL-167.
RX   PubMed=16704422; DOI=10.1111/j.1742-4658.2006.05256.x;
RA   Blanco S., Klimcakova L., Vega F.M., Lazo P.A.;
RT   "The subcellular localization of vaccinia-related kinase-2 (VRK2) isoforms
RT   determines their different effect on p53 stability in tumour cell lines.";
RL   FEBS J. 273:2487-2504(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 3; 4 AND 5).
RA   Suriyapperuma S.P., Sarfarazi M.;
RT   "Identification of 6 different isoforms for Vaccinia-related kinase 2
RT   (VRK2) gene.";
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Colon;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Testis;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT VAL-167.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, AND AUTOPHOSPHORYLATION.
RX   PubMed=14645249; DOI=10.1074/jbc.m310813200;
RA   Nichols R.J., Traktman P.;
RT   "Characterization of three paralogous members of the Mammalian vaccinia
RT   related kinase family.";
RL   J. Biol. Chem. 279:7934-7946(2004).
RN   [10]
RP   INTERACTION WITH EPSTEIN-BARR VIRUS BHRF1 (MICROBIAL INFECTION).
RX   PubMed=16963744; DOI=10.1099/vir.0.81953-0;
RA   Li L.Y., Liu M.Y., Shih H.M., Tsai C.H., Chen J.Y.;
RT   "Human cellular protein VRK2 interacts specifically with Epstein-Barr virus
RT   BHRF1, a homologue of Bcl-2, and enhances cell survival.";
RL   J. Gen. Virol. 87:2869-2878(2006).
RN   [11]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=16495336; DOI=10.1091/mbc.e05-12-1179;
RA   Nichols R.J., Wiebe M.S., Traktman P.;
RT   "The vaccinia-related kinases phosphorylate the N' terminus of BAF,
RT   regulating its interaction with DNA and its retention in the nucleus.";
RL   Mol. Biol. Cell 17:2451-2464(2006).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH MAP3K7.
RX   PubMed=17709393; DOI=10.1128/mcb.00025-07;
RA   Blanco S., Santos C., Lazo P.A.;
RT   "Vaccinia-related kinase 2 modulates the stress response to hypoxia
RT   mediated by TAK1.";
RL   Mol. Cell. Biol. 27:7273-7283(2007).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-336, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [14]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH RAN, AND ACTIVITY
RP   REGULATION.
RX   PubMed=18617507; DOI=10.1074/mcp.m700586-mcp200;
RA   Sanz-Garcia M., Lopez-Sanchez I., Lazo P.A.;
RT   "Proteomics identification of nuclear Ran GTPase as an inhibitor of human
RT   VRK1 and VRK2 (vaccinia-related kinase) activities.";
RL   Mol. Cell. Proteomics 7:2199-2214(2008).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, AND INTERACTION WITH MAPK8IP1; MAPK3K7 AND
RP   MAP2K7.
RX   PubMed=18286207; DOI=10.1371/journal.pone.0001660;
RA   Blanco S., Sanz-Garcia M., Santos C.R., Lazo P.A.;
RT   "Modulation of interleukin-1 transcriptional response by the interaction
RT   between VRK2 and the JIP1 scaffold protein.";
RL   PLoS ONE 3:E1660-E1660(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH MAP2K1 AND KSR1, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=20679487; DOI=10.1128/mcb.01581-09;
RA   Fernandez I.F., Blanco S., Lozano J., Lazo P.A.;
RT   "VRK2 inhibits mitogen-activated protein kinase signaling and inversely
RT   correlates with ErbB2 in human breast cancer.";
RL   Mol. Cell. Biol. 30:4687-4697(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-406, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   INTERACTION WITH VACCINIA VIRUS PROTEIN B12 (MICROBIAL INFECTION).
RX   PubMed=31341052; DOI=10.1128/jvi.00855-19;
RA   Rico A.B., Wang Z., Olson A.T., Linville A.C., Bullard B.L., Weaver E.A.,
RA   Jones C., Wiebe M.S.;
RT   "The Vaccinia Virus (VACV) B1 and Cellular VRK2 Kinases Promote VACV
RT   Replication Factory Formation through Phosphorylation-Dependent Inhibition
RT   of VACV B12.";
RL   J. Virol. 93:0-0(2019).
RN   [21]
RP   INTERACTION WITH VACCINIA VIRUS PROTEIN B12 (MICROBIAL INFECTION).
RX   PubMed=33177193; DOI=10.1128/jvi.02114-20;
RA   Rico A.B., Linville A.C., Olson A.T., Wang Z., Wiebe M.S.;
RT   "The Vaccinia Virus B12 Pseudokinase Represses Viral Replication via
RT   Interaction with the Cellular Kinase VRK1 and Activation of the Antiviral
RT   Effector BAF.";
RL   J. Virol. 95:0-0(2021).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 14-335.
RX   PubMed=19141289; DOI=10.1016/j.str.2008.10.018;
RA   Scheeff E.D., Eswaran J., Bunkoczi G., Knapp S., Manning G.;
RT   "Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a
RT   highly conserved kinase fold, and a putative regulatory binding site.";
RL   Structure 17:128-138(2009).
RN   [23]
RP   VARIANTS [LARGE SCALE ANALYSIS] ASP-50; MET-157 AND VAL-167.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine kinase that regulates several signal
CC       transduction pathways (PubMed:16704422, PubMed:14645249,
CC       PubMed:16495336, PubMed:17709393, PubMed:18617507, PubMed:18286207,
CC       PubMed:20679487). Isoform 1 modulates the stress response to hypoxia
CC       and cytokines, such as interleukin-1 beta (IL1B) and this is dependent
CC       on its interaction with MAPK8IP1, which assembles mitogen-activated
CC       protein kinase (MAPK) complexes (PubMed:17709393). Inhibition of signal
CC       transmission mediated by the assembly of MAPK8IP1-MAPK complexes
CC       reduces JNK phosphorylation and JUN-dependent transcription
CC       (PubMed:18286207). Phosphorylates 'Thr-18' of p53/TP53, histone H3, and
CC       may also phosphorylate MAPK8IP1 (PubMed:16704422). Phosphorylates BANF1
CC       and disrupts its ability to bind DNA and reduces its binding to LEM
CC       domain-containing proteins (PubMed:16495336). Down-regulates the
CC       transactivation of transcription induced by ERBB2, HRAS, BRAF, and MEK1
CC       (PubMed:20679487). Blocks the phosphorylation of ERK in response to
CC       ERBB2 and HRAS (PubMed:20679487). Can also phosphorylate the following
CC       substrates that are commonly used to establish in vitro kinase
CC       activity: casein, MBP and histone H2B, but it is not sure that this is
CC       physiologically relevant (PubMed:14645249).
CC       {ECO:0000269|PubMed:14645249, ECO:0000269|PubMed:16495336,
CC       ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:17709393,
CC       ECO:0000269|PubMed:18286207, ECO:0000269|PubMed:18617507,
CC       ECO:0000269|PubMed:20679487}.
CC   -!- FUNCTION: [Isoform 2]: Phosphorylates 'Thr-18' of p53/TP53, as well as
CC       histone H3. Reduces p53/TP53 ubiquitination by MDM2, promotes p53/TP53
CC       acetylation by EP300 and thereby increases p53/TP53 stability and
CC       activity. {ECO:0000269|PubMed:16704422}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC         Evidence={ECO:0000269|PubMed:16495336};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:17990;
CC         Evidence={ECO:0000269|PubMed:16495336};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1; Evidence={ECO:0000269|PubMed:16495336,
CC         ECO:0000269|PubMed:16704422};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:46609;
CC         Evidence={ECO:0000269|PubMed:16495336, ECO:0000269|PubMed:16704422};
CC   -!- ACTIVITY REGULATION: RAN inhibits its autophosphorylation and its
CC       ability to phosphorylate histone H3. {ECO:0000269|PubMed:18617507}.
CC   -!- SUBUNIT: Isoform 1 interacts with MAP3K7, MAP2K7, MAP2K1 and KSR1
CC       (PubMed:20679487, PubMed:17709393, PubMed:18286207). Isoform 1 and
CC       isoform 2 interact with RAN and MAPK8IP1 (PubMed:18286207,
CC       PubMed:18617507). {ECO:0000269|PubMed:17709393,
CC       ECO:0000269|PubMed:18286207, ECO:0000269|PubMed:18617507,
CC       ECO:0000269|PubMed:20679487}.
CC   -!- SUBUNIT: (Microbial infection) Isoform 1 interacts with Epstein-Barr
CC       virus BHRF1; this interaction is involved in protecting cells from
CC       apoptosis. {ECO:0000269|PubMed:16963744}.
CC   -!- SUBUNIT: (Microbial infection) Isoform 1 interacts with vaccinia
CC       protein B12. {ECO:0000269|PubMed:31341052,
CC       ECO:0000269|PubMed:33177193}.
CC   -!- INTERACTION:
CC       Q86Y07; Q13520: AQP6; NbExp=3; IntAct=EBI-1207615, EBI-13059134;
CC       Q86Y07; P36382: GJA5; NbExp=3; IntAct=EBI-1207615, EBI-750433;
CC       Q86Y07; Q8IVT5: KSR1; NbExp=4; IntAct=EBI-1207615, EBI-486984;
CC       Q86Y07; Q02750: MAP2K1; NbExp=2; IntAct=EBI-1207615, EBI-492564;
CC       Q86Y07; Q8N4V1: MMGT1; NbExp=3; IntAct=EBI-1207615, EBI-6163737;
CC       Q86Y07; Q0VAB0: TBXA2R; NbExp=3; IntAct=EBI-1207615, EBI-18271435;
CC       Q86Y07; Q9NUH8: TMEM14B; NbExp=3; IntAct=EBI-1207615, EBI-8638294;
CC       Q86Y07; Q6UW68: TMEM205; NbExp=3; IntAct=EBI-1207615, EBI-6269551;
CC       Q86Y07; Q6PEY1: TMEM88; NbExp=3; IntAct=EBI-1207615, EBI-17198826;
CC       Q86Y07; P03182: BHRF1; Xeno; NbExp=7; IntAct=EBI-1207615, EBI-1207659;
CC       Q86Y07-1; Q07817-1: BCL2L1; NbExp=2; IntAct=EBI-1207633, EBI-287195;
CC       Q86Y07-1; Q02750: MAP2K1; NbExp=2; IntAct=EBI-1207633, EBI-492564;
CC       Q86Y07-1; Q13469: NFATC2; NbExp=3; IntAct=EBI-1207633, EBI-716258;
CC       Q86Y07-1; P62826: RAN; NbExp=2; IntAct=EBI-1207633, EBI-286642;
CC       Q86Y07-1; Q61097: Ksr1; Xeno; NbExp=8; IntAct=EBI-1207633, EBI-1536336;
CC       Q86Y07-1; Q62073: Map3k7; Xeno; NbExp=3; IntAct=EBI-1207633, EBI-1775345;
CC       Q86Y07-1; Q60591: Nfatc2; Xeno; NbExp=2; IntAct=EBI-1207633, EBI-643104;
CC       Q86Y07-1; Q8CF89: Tab1; Xeno; NbExp=2; IntAct=EBI-1207633, EBI-1778503;
CC       Q86Y07-2; Q13469: NFATC2; NbExp=4; IntAct=EBI-1207636, EBI-716258;
CC       Q86Y07-2; Q9WVI9-2: Mapk8ip1; Xeno; NbExp=2; IntAct=EBI-1207636, EBI-288464;
CC       Q86Y07-5; P62826: RAN; NbExp=2; IntAct=EBI-1207649, EBI-286642;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cytoplasm
CC       {ECO:0000269|PubMed:16704422}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:16704422}; Single-pass type IV membrane protein
CC       {ECO:0000255}. Mitochondrion membrane {ECO:0000269|PubMed:16704422};
CC       Single-pass type IV membrane protein {ECO:0000255}. Nucleus envelope
CC       {ECO:0000250|UniProtKB:Q8BN21}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm
CC       {ECO:0000269|PubMed:16704422}. Nucleus {ECO:0000269|PubMed:16704422}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1; Synonyms=VRK2A {ECO:0000303|PubMed:16704422};
CC         IsoId=Q86Y07-1; Sequence=Displayed;
CC       Name=2; Synonyms=VRK2B {ECO:0000303|PubMed:16704422};
CC         IsoId=Q86Y07-2; Sequence=VSP_008537, VSP_008538;
CC       Name=3;
CC         IsoId=Q86Y07-3; Sequence=VSP_008533;
CC       Name=4; Synonyms=5;
CC         IsoId=Q86Y07-4; Sequence=VSP_008534;
CC       Name=5; Synonyms=6;
CC         IsoId=Q86Y07-5; Sequence=VSP_008535, VSP_008536;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 are expressed in various
CC       tumor cell lines. Expression of isoform 1 inversely correlates with
CC       ERBB2 in breast carcinomas (at protein level). Widely expressed. Highly
CC       expressed in fetal liver, skeletal muscle, pancreas, heart, peripheral
CC       blood leukocytes and testis. {ECO:0000269|PubMed:16704422,
CC       ECO:0000269|PubMed:20679487, ECO:0000269|PubMed:9344656}.
CC   -!- PTM: [Isoform 1]: Autophosphorylated. {ECO:0000269|PubMed:14645249,
CC       ECO:0000269|PubMed:16704422}.
CC   -!- PTM: [Isoform 2]: Autophosphorylated. {ECO:0000269|PubMed:16704422}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CK1 Ser/Thr
CC       protein kinase family. VRK subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD54446.2; Type=Miscellaneous discrepancy; Note=Aberrant splicing.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/VRK2ID42799ch2p16.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB000450; BAA19109.1; -; mRNA.
DR   EMBL; AJ512204; CAD54446.2; ALT_SEQ; mRNA.
DR   EMBL; AY228367; AAO73047.1; -; mRNA.
DR   EMBL; AY228368; AAO73048.1; -; mRNA.
DR   EMBL; AY228369; AAO73049.1; -; mRNA.
DR   EMBL; AY228370; AAO73050.1; -; mRNA.
DR   EMBL; AY228371; AAO73051.1; -; mRNA.
DR   EMBL; AY228372; AAO73052.1; -; mRNA.
DR   EMBL; AK296611; BAG59222.1; -; mRNA.
DR   EMBL; AK223540; BAD97260.1; -; mRNA.
DR   EMBL; AC007250; AAY15019.1; -; Genomic_DNA.
DR   EMBL; AC068193; AAX93262.1; -; Genomic_DNA.
DR   EMBL; AC073215; AAY14648.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00062.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00064.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00066.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00067.1; -; Genomic_DNA.
DR   EMBL; CH471053; EAX00068.1; -; Genomic_DNA.
DR   EMBL; BC027854; AAH27854.1; -; mRNA.
DR   CCDS; CCDS1859.1; -. [Q86Y07-1]
DR   CCDS; CCDS46291.1; -. [Q86Y07-5]
DR   CCDS; CCDS46292.1; -. [Q86Y07-3]
DR   RefSeq; NP_001123952.1; NM_001130480.2. [Q86Y07-1]
DR   RefSeq; NP_001123953.1; NM_001130481.2. [Q86Y07-1]
DR   RefSeq; NP_001123954.1; NM_001130482.2. [Q86Y07-3]
DR   RefSeq; NP_001123955.1; NM_001130483.2. [Q86Y07-5]
DR   RefSeq; NP_001275765.1; NM_001288836.1. [Q86Y07-4]
DR   RefSeq; NP_001275766.1; NM_001288837.1. [Q86Y07-1]
DR   RefSeq; NP_001275767.1; NM_001288838.1. [Q86Y07-5]
DR   RefSeq; NP_001275768.1; NM_001288839.1. [Q86Y07-4]
DR   RefSeq; NP_006287.2; NM_006296.6. [Q86Y07-1]
DR   RefSeq; XP_005264597.1; XM_005264540.4. [Q86Y07-1]
DR   RefSeq; XP_006712153.1; XM_006712090.3. [Q86Y07-2]
DR   RefSeq; XP_006712154.1; XM_006712091.3. [Q86Y07-5]
DR   RefSeq; XP_006712155.1; XM_006712092.3. [Q86Y07-4]
DR   RefSeq; XP_006712156.1; XM_006712093.3. [Q86Y07-4]
DR   RefSeq; XP_011531394.1; XM_011533092.2. [Q86Y07-1]
DR   RefSeq; XP_016860347.1; XM_017004858.1. [Q86Y07-2]
DR   RefSeq; XP_016860348.1; XM_017004859.1. [Q86Y07-4]
DR   RefSeq; XP_016860349.1; XM_017004860.1. [Q86Y07-4]
DR   RefSeq; XP_016860350.1; XM_017004861.1. [Q86Y07-4]
DR   RefSeq; XP_016860351.1; XM_017004862.1. [Q86Y07-4]
DR   RefSeq; XP_016860352.1; XM_017004863.1. [Q86Y07-4]
DR   PDB; 2V62; X-ray; 1.70 A; A/B=14-335.
DR   PDB; 5UU1; X-ray; 2.00 A; A=14-335.
DR   PDB; 6NCG; X-ray; 2.45 A; A/B=14-335.
DR   PDBsum; 2V62; -.
DR   PDBsum; 5UU1; -.
DR   PDBsum; 6NCG; -.
DR   AlphaFoldDB; Q86Y07; -.
DR   SMR; Q86Y07; -.
DR   BioGRID; 113283; 256.
DR   IntAct; Q86Y07; 60.
DR   MINT; Q86Y07; -.
DR   STRING; 9606.ENSP00000408002; -.
DR   BindingDB; Q86Y07; -.
DR   ChEMBL; CHEMBL1649059; -.
DR   DrugCentral; Q86Y07; -.
DR   iPTMnet; Q86Y07; -.
DR   PhosphoSitePlus; Q86Y07; -.
DR   BioMuta; VRK2; -.
DR   DMDM; 90116515; -.
DR   EPD; Q86Y07; -.
DR   jPOST; Q86Y07; -.
DR   MassIVE; Q86Y07; -.
DR   MaxQB; Q86Y07; -.
DR   PaxDb; Q86Y07; -.
DR   PeptideAtlas; Q86Y07; -.
DR   PRIDE; Q86Y07; -.
DR   ProteomicsDB; 70345; -. [Q86Y07-1]
DR   ProteomicsDB; 70346; -. [Q86Y07-2]
DR   ProteomicsDB; 70347; -. [Q86Y07-3]
DR   ProteomicsDB; 70348; -. [Q86Y07-4]
DR   ProteomicsDB; 70349; -. [Q86Y07-5]
DR   Antibodypedia; 30474; 216 antibodies from 29 providers.
DR   DNASU; 7444; -.
DR   Ensembl; ENST00000340157.9; ENSP00000342381.4; ENSG00000028116.18. [Q86Y07-1]
DR   Ensembl; ENST00000412104.6; ENSP00000404156.3; ENSG00000028116.18. [Q86Y07-4]
DR   Ensembl; ENST00000417641.6; ENSP00000402375.2; ENSG00000028116.18. [Q86Y07-5]
DR   Ensembl; ENST00000435505.6; ENSP00000408002.2; ENSG00000028116.18. [Q86Y07-1]
DR   Ensembl; ENST00000440705.6; ENSP00000398323.2; ENSG00000028116.18. [Q86Y07-3]
DR   Ensembl; ENST00000648897.1; ENSP00000497378.1; ENSG00000028116.18. [Q86Y07-2]
DR   GeneID; 7444; -.
DR   KEGG; hsa:7444; -.
DR   MANE-Select; ENST00000340157.9; ENSP00000342381.4; NM_006296.7; NP_006287.2.
DR   UCSC; uc002rzo.3; human. [Q86Y07-1]
DR   CTD; 7444; -.
DR   DisGeNET; 7444; -.
DR   GeneCards; VRK2; -.
DR   HGNC; HGNC:12719; VRK2.
DR   HPA; ENSG00000028116; Low tissue specificity.
DR   MalaCards; VRK2; -.
DR   MIM; 602169; gene.
DR   neXtProt; NX_Q86Y07; -.
DR   OpenTargets; ENSG00000028116; -.
DR   PharmGKB; PA37331; -.
DR   VEuPathDB; HostDB:ENSG00000028116; -.
DR   eggNOG; KOG1164; Eukaryota.
DR   GeneTree; ENSGT00940000158042; -.
DR   HOGENOM; CLU_019279_4_3_1; -.
DR   InParanoid; Q86Y07; -.
DR   OMA; YCESQIL; -.
DR   OrthoDB; 866200at2759; -.
DR   PhylomeDB; Q86Y07; -.
DR   TreeFam; TF106473; -.
DR   PathwayCommons; Q86Y07; -.
DR   Reactome; R-HSA-2980766; Nuclear Envelope Breakdown. [Q86Y07-2]
DR   Reactome; R-HSA-2995383; Initiation of Nuclear Envelope (NE) Reformation. [Q86Y07-2]
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013404; RAC2 GTPase cycle.
DR   Reactome; R-HSA-9013405; RHOD GTPase cycle.
DR   Reactome; R-HSA-9013408; RHOG GTPase cycle.
DR   Reactome; R-HSA-9013423; RAC3 GTPase cycle.
DR   SignaLink; Q86Y07; -.
DR   SIGNOR; Q86Y07; -.
DR   BioGRID-ORCS; 7444; 13 hits in 1118 CRISPR screens.
DR   ChiTaRS; VRK2; human.
DR   EvolutionaryTrace; Q86Y07; -.
DR   GeneWiki; VRK2; -.
DR   GenomeRNAi; 7444; -.
DR   Pharos; Q86Y07; Tbio.
DR   PRO; PR:Q86Y07; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q86Y07; protein.
DR   Bgee; ENSG00000028116; Expressed in monocyte and 199 other tissues.
DR   ExpressionAtlas; Q86Y07; baseline and differential.
DR   Genevisible; Q86Y07; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0031966; C:mitochondrial membrane; IDA:UniProtKB.
DR   GO; GO:0005635; C:nuclear envelope; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019904; F:protein domain specific binding; IDA:MGI.
DR   GO; GO:0019901; F:protein kinase binding; IDA:MGI.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0034599; P:cellular response to oxidative stress; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:2000659; P:regulation of interleukin-1-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043408; P:regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cytoplasm;
KW   Endoplasmic reticulum; Host-virus interaction; Kinase; Membrane;
KW   Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..508
FT                   /note="Serine/threonine-protein kinase VRK2"
FT                   /id="PRO_0000086806"
FT   TRANSMEM        487..507
FT                   /note="Helical; Anchor for type IV membrane protein"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          29..319
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          397..508
FT                   /note="Interaction with MAP3K7"
FT                   /evidence="ECO:0000269|PubMed:17709393"
FT   ACT_SITE        166
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         35..43
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         61
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         336
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18691976"
FT   MOD_RES         406
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..118
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039, ECO:0000303|Ref.3"
FT                   /id="VSP_008534"
FT   VAR_SEQ         1..23
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_008533"
FT   VAR_SEQ         395..397
FT                   /note="EST -> VEA (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16704422"
FT                   /id="VSP_008537"
FT   VAR_SEQ         395..396
FT                   /note="ES -> FR (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_008535"
FT   VAR_SEQ         397..508
FT                   /note="Missing (in isoform 5)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_008536"
FT   VAR_SEQ         398..508
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16704422"
FT                   /id="VSP_008538"
FT   VARIANT         50
FT                   /note="N -> D (in dbSNP:rs34130684)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041293"
FT   VARIANT         157
FT                   /note="I -> M (in dbSNP:rs35966666)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041294"
FT   VARIANT         167
FT                   /note="I -> V (in dbSNP:rs1051061)"
FT                   /evidence="ECO:0000269|PubMed:15489334,
FT                   ECO:0000269|PubMed:16704422, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:9344656"
FT                   /id="VAR_017095"
FT   VARIANT         211
FT                   /note="N -> S (in dbSNP:rs36081172)"
FT                   /id="VAR_051681"
FT   CONFLICT        419
FT                   /note="K -> E (in Ref. 3; AAO73048/AAO73049/AAO73051)"
FT                   /evidence="ECO:0000305"
FT   STRAND          20..22
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   STRAND          28..34
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   STRAND          43..51
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           53..55
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   STRAND          58..64
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   STRAND          65..67
FT                   /evidence="ECO:0007829|PDB:5UU1"
FT   HELIX           69..80
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           83..93
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   STRAND          103..113
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   STRAND          115..122
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   STRAND          124..127
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           128..131
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           134..136
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           140..159
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           169..171
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   STRAND          172..178
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   STRAND          181..184
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           187..189
FT                   /evidence="ECO:0007829|PDB:6NCG"
FT   STRAND          191..194
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           195..197
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           206..208
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   TURN            214..216
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           219..223
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           229..245
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           251..253
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           257..269
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   TURN            270..272
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           273..278
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           286..296
FT                   /evidence="ECO:0007829|PDB:2V62"
FT   HELIX           306..313
FT                   /evidence="ECO:0007829|PDB:2V62"
SQ   SEQUENCE   508 AA;  58141 MW;  9F3F6FCC9280568F CRC64;
     MPPKRNEKYK LPIPFPEGKV LDDMEGNQWV LGKKIGSGGF GLIYLAFPTN KPEKDARHVV
     KVEYQENGPL FSELKFYQRV AKKDCIKKWI ERKQLDYLGI PLFYGSGLTE FKGRSYRFMV
     MERLGIDLQK ISGQNGTFKK STVLQLGIRM LDVLEYIHEN EYVHGDIKAA NLLLGYKNPD
     QVYLADYGLS YRYCPNGNHK QYQENPRKGH NGTIEFTSLD AHKGVALSRR SDVEILGYCM
     LRWLCGKLPW EQNLKDPVAV QTAKTNLLDE LPQSVLKWAP SGSSCCEIAQ FLVCAHSLAY
     DEKPNYQALK KILNPHGIPL GPLDFSTKGQ SINVHTPNSQ KVDSQKAATK QVNKAHNRLI
     EKKVHSERSA ESCATWKVQK EEKLIGLMNN EAAQESTRRR QKYQESQEPL NEVNSFPQKI
     SYTQFPNSFY EPHQDFTSPD IFKKSRSPSW YKYTSTVSTG ITDLESSTGL WPTISQFTLS
     EETNADVYYY RIIIPVLLML VFLALFFL
//
